Allan Seibert, MD
Pulmonary Disease · Mobile, ALNPI 1801872353
Payments from drug & device makers
Across 333 payments — averaging $7098.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech, Inc.$994K
- Gilead$588K
- GSK$485K
- Sanofi US Services Inc.$149K
- Hoffmann-la Roche Limited$84K
- AstraZeneca$42K
- plus $23K from 21 others
What the payments were for
- Food & beverage$3,11599%
- Education$231%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech, Inc. | 35 | $993,699 |
| Gilead | 24 | $587,800 |
| GSK | 104 | $485,472 |
| Sanofi US Services Inc. | 42 | $148,629 |
| Hoffmann-la Roche Limited | 4 | $83,641 |
| AstraZeneca(2 entities) | 21 | $41,559 |
| Boehringer Ingelheim | 29 | $11,760 |
| Chiesi USA, Inc. | 1 | $9,000 |
| Pfizer | 2 | $1,011 |
| Insmed, Inc. | 11 | $240 |
| Mylan Specialty L.p. | 9 | $173 |
| Philips North America LLC | 11 | $156 |
| Mallinckrodt Hospital Products Inc. | 4 | $134 |
| Sunovion Pharmaceuticals Inc. | 8 | $109 |
| Regeneron Healthcare Solutions, Inc. | 4 | $82 |
| Jazz Pharmaceuticals Inc. | 2 | $67 |
| Grifols USA, LLC | 3 | $55 |
| Electromed, Inc. | 5 | $49 |
| Actelion Pharmaceuticals US, Inc. | 2 | $45 |
| Baxter Healthcare | 2 | $39 |
| Pulmonx Corporation | 2 | $38 |
| Verona Pharma, Inc. | 2 | $38 |
| Sanofi | 2 | $38 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $31 |
| Viatris Specialty LLC | 1 | $19 |
| Genentech USA, Inc. | 1 | $18 |
| Shire North American Group Inc | 1 | $18 |
How this compares
$2,363,919 in reported general payments places this provider in the 95th percentile of 215 pulmonary disease providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 702 | $560,035 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 176 | $145,355 |
| OfevNintedanib Esylate | 11 | $138,967 |
| Spiriva RespimatTiotropium Bromide | 141 | $87,071 |
| Breo ElliptaFluticasone/Vilanterol | 142 | $71,734 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 52 | $33,047 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 58 | $32,019 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 40 | $26,705 |
| EliquisApixaban | 34 | $24,348 |
| SymbicortBudesonide/Formoterol Fumarate | 86 | $23,913 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 499 | $14,026 |
| XareltoRivaroxaban | 14 | $11,515 |
| Incruse ElliptaUmeclidinium Bromide | 24 | $8,391 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 59 | $7,183 |
| Fluticasone Propionate HfaFluticasone Propionate | 17 | $6,354 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $485,472 | $677,790943 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Combivent Respimat, Stiolto Respimat | $11,760 | $285,789244 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $41,559 | $169,267262 claims |
| PfizerEliquis | $1,011 | $24,34834 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 215 pulmonary disease providers in Alabama.
Other pulmonary disease in Mobile
- Adrian DivittorioMobile$212K
- Peter LutzMobile$102K
- Johnson HaynesMobile$50K
- Virginia RadcliffMobile$23K
- Brian FoutyMobile$21K
- Cynthia CrowderMobile$20K
- Philip AlmaloufMobile$14K
- Campbell SindelMobile$14K
- Chibuzo OdigweMobile$14K
- Caesar AgaganMobile$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.